Page 57 - Solid Tumors News Today

Mutations That Drive Therapy-related Neoplasms in Kids by Angela Mohan on  February 12, 2021 at 11:44 AM A paper detailing the work was published in Nature Communications. The somatic (cancer) and germline (inherited) genomic alterations that drive therapy-related myeloid neoplasms in children have not been comprehensively described, until now. The researchers used a variety of sequencing techniques (whole exome, whole genome and RNA) to characterize the genomic profile of 8...

Published: Feb 10, 2021   - Submission Based on Positive Pivotal innovaTV 204 Trial Results Presented at the European Society of Medical Oncology Virtual Congress 2020 -   BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Seagen, Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for tisotumab vedotin. This BLA requests FDA approval of ...

Search jobs 11-Feb-2021 Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer Company Announcement Submission based on positive pivotal innovaTV 204 trial results presented at the European Society of Medical Oncolo...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Share this article Share this article ROCKLAND, Mass., Feb. 3, 2021 /PRNewswire/ -- EMD Serono, the healthcare business sector of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that the US Food and Drug Administration (FDA) has approved TEPMETKO ® (tepotinib) following Priority Review for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition ( MET) exon 14 skipping alterations. This indication is ap...

Key Findings of the Report: • The global Drugs for Solid Tumors market forecast is studied from 2021 to 2027. • The research study includes a thorough analysis of the current research and clinical developments in the market globally. • The report presents a market definition along with the list of leading players and analyses their strategies to determine the competitive outlook of the market. • The report also studies the drivers, restraints, opportunities, and challenges of the global...

Published: Jan 25, 2021 (margetuximab-cmkb) trastuzumab), both with chemotherapy In the U.S., MARGENZA is approved, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease ROCKVILLE, MD, Jan. 25, 2021 (GLOBE NEWSWIRE) --MacroGenics, Inc.. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innova...

(2) KEYTRUDA Is First Checkpoint Inhibitor Approved in Europe to Treat MSI-H or dMMR Colorectal Cancer European Approval Based on Results From KEYNOTE-177 Trial Demonstrating KEYTRUDA Significantly Reduced Risk of Disease Progression or Death by 40% Compared With Chemotherapy Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the European Commission has approved KEYTRUDA, Mercks anti-PD-1 therapy, as a monotherapy for the first-line treatment of adult pa...

Solid tumors, such as breast cancers can be targeted by boosting our immune system T cells via the addition of a small molecule to the treatment procedure called chimeric antigen receptor-T (CAR-T) cell therapy.

ADC Contract Manufacturing Market, 2020-2030 New York, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "ADC Contract Manufacturing Market, 2020-2030" - https://www.reportlinker.com/p03290025/?utm_source=GNW Over time, clinical researchers have been able to further their understanding of the intricacies of ADC design and have also improved the development process of these complex pharmacological interventions. Some of the recently approved ADC therapeu...